Johnson & Johnson MedTech Receives FDA Approval for the Varipulse Pulsed Field Ablation Platform for the Treatment of Atrial Fibrillation
November 08, 2024
November 08, 2024
NEW BRUNSWICK, New Jersey, Nov. 8 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
The VARIPULSE Platform is the first and only Pulsed Field Ablation (PFA) System in the U.S. fully integrated with the CARTO 3 Electro-anatomical Mapping System, driving efficiency, reproducibility and accuracy/1
Approval is supported by the admIRE study, where 85% peak primary effectiveness 12-month success and minimal-to-no fluoroscopy were achieved/2 . . .
* * *
The VARIPULSE Platform is the first and only Pulsed Field Ablation (PFA) System in the U.S. fully integrated with the CARTO 3 Electro-anatomical Mapping System, driving efficiency, reproducibility and accuracy/1
Approval is supported by the admIRE study, where 85% peak primary effectiveness 12-month success and minimal-to-no fluoroscopy were achieved/2 . . .